{'fraction_non_alphanumeric': 0.034653465346534656, 'fraction_numerical': 0.0, 'mean_word_length': 5.175572519083969, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Influenza vaccine: split-product versus whole-virus types--How do they differ.

Although the swine-influenza-immunization campaign has been suspended for all but high-risk groups, it was attended by other problems besides the well publicized but very rare apparent association with Guillain-Barre syndrome. One of these other problems relates to the difference between split-product and whole-virus types of vaccines, a difference not generally appreciated by physicians. The problem is worth discussing because the basic principles apply to the manufacture of influenza vaccines other than the current swine-virus vaccine. Different manufacturing processes have been developed in the hope of minimizing reactivity (systemic type, fever, malaise, headache and myalgia; local type, arm pain, redness and . . .